Agilvax
Private company that discovers and develops immunotherapies to combat cancer & targeted vaccines against infectious diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$6—9m (Dealroom.co estimates Jan 2020.)
Albuquerque New Mexico (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Seed | |
| N/A | $1.2m | Early VC | |
$2.0m | Series A | ||
$500k | Series A | ||
$2.3m | Grant | ||
$2.0m | Grant | ||
| N/A | $1.5m | Series A | |
| Total Funding | $9.5m | ||
Related Content
Recent News about Agilvax
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.